impairment compared to normal controls, while a widespread pattern of cortical thinning was observed in patients with cognitive impairment 23 . Decreased FA has been reported in the splenium of the corpus callosum 24 .
The frequency and importance of cognitive impairment in multiple sclerosis (MS) is well recognised 1 . Domains of cognition most frequently affected are: episodic and working memory, attention, and speed of information processing. In this issue of the Journal, Feinstein et al describe their findings in a cohort of 62 MS patients evaluated for the relative importance of diffusion tensor imaging (DTI) derived indices of normal appearing white matter (NAWM) and grey matter (NAGM) on determining cognitive impairment 2 . Their main finding is that fractional anisotropy (FA) of NAWM emerged as a significant predictor of cognitive impairment, adding to the variance derived from lesion and atrophy data. This means that cognitive impairment cannot be entirely explained by brain atrophy and T1 and T2 lesion volumes.
The authors explain in part their low percentage (18%) of cognitive impairment by a higher education level. A more common yield is 40%, but we are attaining similar low numbers in our MS population. This might reflect the fact that there is a trend towards a more benign course of MS, as has been the case in recent therapeutic trials. Feinstein's cohort includes early MS patients, in whom the ability to predict cognitive deficits by MRI parameters is of particular importance because of the profound impact of cognitive impairments on employment, autonomy, quality of life, and relationships 1 , especially at a young age.
This work adds to an increasing amount of data showing that images obtained by magnetisation transfer ratio (MTR) can detect early damage even outside established lesions. A low MTR reflects several structural abnormalities, including diffuse astrocytic hyperplasia, patchy oedema, perivascular cellular infiltrates, abnormally thin myelin, and axonal damage, which reduce the mobility of protons 3 . Several studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] demonstrate the unique role of MTR as a marker of cognitive impairment.
Diffusion tensor imaging includes measures of mean diffusivity, which is affected by cell size and integrity, and of fractional anisotropy which indicates the degree of structural integrity and structural alignment within fibre tracts 6 . Several studies report an association between cognitive impairment (specific or global) and FA in the parenchyma 13 , the NAWM 14 , the fronto-lateral area 15 and within the normal appearing corpus callosum 16 . The association between cognitive deficits and mean diffusivity in the NAGM 17 and within the parenchyma 18 has also been described. Most studies show a correlation between DTI indices and cognition 19, 20 . Other parameters, including the apparent diffusivity coefficient (ADC) 15, 21 and entropy 18 were also associated with cognition. Another study has documented the role of cortical lesions in cognition impairment. Double inversion recovery allows visualization of cortical lesions. Cognitively impaired patients have a higher cortical lesion volume and decreased normalized neocortical gray matter volume, when compared with cognitively unimpaired patients 22 . Regional analysis revealed significant cortical thinning in frontal and temporal regions of RRMS patients without cognitive criteria. We can infer that these lesions disrupt, to varying degrees, tracts, both intra and intercortical, and intra and interhemispheric involved in brain connectivity, thus explaining disturbances of memory, attention and information processing, which depend on such connectivity. Longitudinal MR studies show progressive atrophy of the GM, thalamus and hippocampus, incompletely related to T2 lesion volume (linked to inflammation), a possible indication that a degenerative process, distinct from inflammation, runs its course, in parallel with immunologically-induced pathology.
We can expect that this process of increasing refinement of correlating cognition with anatomical lesions will accelerate. It will be important to study early MS cases, so as to intervene rapidly in order to lessen the dire consequences of lesions involving structures subserving cognition.
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